LA-MCA 2025 Program by LA-MCA Magazine

March 13 - 16, 2025

CONFIDENCE TO BE

LA-MCA 2025 EXPERT FACULTY

Kian Karimi, MD Course Chairman

Esteemed Planning Committee and Scientific Advisors Speakers

Shino Bay Aguilera, DO

Gal Aharonov, MD

Shawn Allen, MD

Amy Anderson, MBA

Michael Antosy

Daniel Barrett, MD

Julie Bass Kaplan, FNP

George Baxter-Holder, DPN

Charles Boyd, MD

Scott Callahan, PA-C

Lanna Cheuck, DO

Shanna Concepcion, RN

Kate Cunningham, PA-C

Sarah Dalhoumi, MD

Steven Dayan, MD

Josh DeBlasio

Candice Dery, RDMS

Adrienne Easterling, PA-C

Lisa Espinoza, MD

Sabrina Fabi, MD

Amy Faircloth, RN

Angela O’Mara Program Director

Giles Raine Director Industry Partnerships

Neil Foster

Zena Gabriel, MD

Gina Goick Magnum

Dan Grauer, DDS

Alex Grazier

Lisa Grunebaum, MD

Brian Hayes

Jill Hessler, MD

Raffi Hovsepian, MD

Kirstie Jackson

Jeffrey Joseph, MD

John Joseph, MD

Kian Karimi, MD

Saami Khalifian, MD

Joelle Lieman, MD

Amy Lynn, RN

Keith Marcus, MD

Katie Martin, PA-C

Jennifer Murdock, MD

Robin Ntoh

Anil Rajani, MD

Morgan Renfro, RN

Laurence Rifkin, DDS

Kelsey Roelofs, MD

Jared Rohrer

Daniel Rootman, MD

Sara Shikhman, Esq.

Sherly Soleiman, MD

Steven Sorr, NMD

Sharon Stewart, PA

Taylor Szupiany, PA-C

Ben Talei, MD

Leslie Tracey

Christin Trujillo

John Vartanian, MD

Edwin F. Williams, III, MD

Cheryl Wiseman, BSN

Julie Woodward, MD

Saranya Wyles, MD

Francine Young, RN

Sandy Zhang-Nunes, MD

Julie Bass Kaplan, FNP Aesthetic Nursing

Josh DeBlasio Marketing/Business

Saami Khalifian, MD Dermatology

Laurence Rifkin, DDS Aesthetic Dentistry

Sandy Zhang-Nunes, MD Oculoplastic Surgery

John Vartanian, MD Facial Plastic Surgery

VISIT THE GALDERMA BOOTH TO LEARN MORE

HIT™ is a patient-centric and science-based approach leveraging injectors’ expertise and Galderma’s Aesthetic Collection to create an Individualized Treatment Plan. Kiss and Smile is a treatment plan that improves firmness in the cheeks (Sculptra), volumizes and defines lips (Restylane® Kysse), and smooths lines around the mouth (Restylane® Defyne/Restylane® Refyne) for natural-looking results.1-4

REFERENCES: 1. Sculptra. Instructions for Use. Galderma Laboratories, L.P., 2023. 2. Restylane Kysse. Instructions for Use. Galderma Laboratories,

Instructions for Use. Galderma Laboratories, L.P., 2023. 4. Restylane Defyne. Instructions for Use. Galderma Laboratories, L.P.,

SCULPTRA® IMPORTANT SAFETY INFORMATION

Indication: Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies, fine lines and wrinkles in the cheek region, and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the periorbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

RESTYLANE FAMILY IMPORTANT SAFETY INFORMATION

The Restylane family of products are indicated for patients over the age of 21, and includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Kysse, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, and Restylane® Eyelight

APPROVED USES

Restylane® and Restylane-L® are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane® and Restylane-L® are also indicated for injection into the lips.

Restylane® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane® Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss.

Restylane® Silk is for lip augmentation and for correction of perioral wrinkles. Restylane® Kysse is for lip augmentation and for correction of upper perioral wrinkles.

Restylane® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

Restylane® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds. Restylane® Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.

Restylane® Contour is for cheek augmentation and for the correction of midface contour deficiencies.

Restylane® Eyelight is for the improvement of infraorbital hollowing.

Do not use if you have severe allergies with a history of severe reactions (anaphylaxis), are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you have a history of scarring or pigmentation disorders as these side effects can occur with hyaluronic acid fillers. Tell your doctor if you are planning other cosmetic treatments (i.e., lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

Tell your doctor if you’re taking medications that lower your body’s immune response or affect bleeding, such as aspirin or warfarin, as these medications may increase the risk of bruising or bleeding at the gel injection site. Using these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete.

The most common side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

To report a side effect with any Restylane® product, please call Galderma Laboratories, L.P at 1-855-425-8722.

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.

L.P., 2023. 3. Restylane Refyne

2023.

Actual Restylane patient. Individual results may vary.

Thursday, March 13, 2025

Day 1 - Track 1 Scientific Sessions – Main Ballroom

7:30 am REGISTRATION & EXHIBITS OPEN!

9:00 - 9:15 Welcome to LA-MCA 2025!

Kian Karimi, MD – Course Chairman

9:15 - 11:00 FOREHEAD & TEMPLE: Upper Face Surgical & Non-Surgical Approaches

Moderator: Lisa Grunebaum, MD

9:15 - 9:30 Anatomy of the Forehead & Temple Region for Injectors – Morgan Renfro, RN

9:30 - 9:45 Fillers in the Forehead & Temple Regions – Techniques and Tips for Safety and Success – Lisa Grunebaum, MD

9:45 - 10:00 Combining Upper Face Surgery & Injectables to Maximize Natural Results – Jeffrey Joseph, MD

10:00 - 10:15 3D-CT Scan Evidence to Support Reason for Facial Bony Changes Which Occur with Aging – John Joseph, MD

10:15 - 10:30 The Pretrichial Browlift – Julie Woodward, MD

10:30 - 11:00 PANEL With Live Q&A – Lisa Grunebaum, MD, Jeffrey Joseph, MD, John Joseph, MD, Morgan Renfro, RN, Julie Woodward, MD

11:00 - 12:30 FILLER COMPLICATIONS: Dissolving Filler, Vascular Occlusion and Blindness

Moderator: Sandy Zhang-Nunes, MD

11:00 - 11:15 Update on The Dissolvability of Fillers – Sandy Zhang-Nunes, MD

11:15 - 11:30 Vascular Occlusion and Blindness– How and Why Does it Happen and Tips to Avoid? – Dan Rootman, MD

11:30 - 11:45 Ultrasound Guided Treatment of Vascular Occlusion – “Blind Reversal” vs “Visual Reversal” – Candice Dery, RDMS

11:45 - 12:30 SPECIAL PANEL – How Do We Treat Vascular Occlusions? – Julie Bass Kaplan, FNP, Candice Dery, RDMS, Saami Khalifian, MD, Morgan Renfro, RN, Dan Rootman, MD, Sandy Zhang-Nunes, MD

12:30 - 1:30 Lunch with Exhibitors

1:30 - 3:15 EYES & MID-FACE: Surgical & Non-Surgical Approaches

Moderator: Kelsey Roelofs, MD

1:30 - 1:45 Non-Surgical Treatment of the Asymmetric Eyelid – Gal Aharonov, MD

1:45 - 2:00 Lower Lid Rejuvenation with Laser and Injections – Julie Woodward, MD

2:00 - 2:15 Volume Modification During Upper and Lower Blepharoplasty – Kelsey Roelofs, MD

2:15 - 2:30 Neurotoxin Techniques: Eyes & Mid Face – Julie Bass Kaplan, FNP

2:30 - 2:45 Male Facial Balancing with Blended Calcium Hydroxyapatite and High G’Prime Vycross HA Filler – Saami Khalifian, MD

2:45 - 3:00 Periocular Laser Resurfacing – What Are The New Options, and Where Does Surgery Still Play a Role? – Jennifer Murdock, MD

3:00 - 3:15 PANEL With Live Q&A – Gal Aharonov, MD, Julie Bass Kaplan, FNP, Saami Khalifian, MD, Jennifer Murdock, MD, Kelsey Roelofs, MD, Julie Woodward, MD

3:15 - 3:45 Coffee Break with Exhibitors

3:45 - 6:30 LIVE Demo: Regenerative Aesthetics – Highlights from the Industry Non-CME

3:45 - 4:30 Sciton BBL HeroIC and Moxi with LIVE Demo – Kian Karimi, MD & Saami Khalifian, MD

4:30 - 5:15 Regenerative Aesthetics with Radiesse – Kate Cunningham, PA-C, Saranya Wyles, MD

5:15 - 6:30 Trends In Aesthetics Galderma/GAIN Live Demo – Sabrina Fabi, MD, Kian Karimi, MD, Amy Lynn, RN, Morgan Renfro, RN

6:30 - 8:00 Welcome and Cocktail Reception! – Sponsored by Galderma/GAIN, Celebrating 10 years of GAIN!

Help patients treat now and pay over time with Allē Payment Plans

Flexible payment options from Cherry—a leading buy now, pay over time solution in the aesthetics industry*—are available within Allē.

Help meet patients' aesthetic goals

Confidently recommend treatments to meet your patients' needs, knowing they can pay over time.

Lean on trusted partners

Allē, with Cherry, is committed to making aesthetics more accessible. Patients can apply to pay for the aesthetic treatments they love over time not only those from Allergan Aesthetics.

Quick payouts†

Enjoy fast payouts within four business days while Cherry handles the monthly billing with the patient.

For your practice‡

• Apply a patient's approved balance in addition to Allē gift cards and offers, all within the single checkout flow that you already know from Allē.

• Recommend treatments in line with the appropriate dosing schedule to achieve desired outcomes.

• Receive payments for the full§ transaction value of eligible Allergan Aesthetics products and treatments. All other services are subject to standard Cherry rates.

• Build loyalty and increase appropriate treatments by offering them flexible ways to pay. Patients spent twice as much per treatment visit using an Allē Payment Plan.II

For your patients

Allē Members can:

• Apply quickly and easily within Allē, with a soft credit check.

• Receive an instant decision on approval status for up to $10,000 without impacting their credit.

• Pay over time, with interest starting at 0% APR for qualifying applicants, while still earning Allē points.

Payment plans for all patients Resources

For your practice

Allē Payment Plans offer a flexible way for patients to pay for their favorite aesthetic products and treatments—from neurotoxins to dermal fillers, to body contouring and professional grade skincare and more.

Payment plans help make aesthetics more accessible. In fact, 19% of patients joined Allē for the first time to use payment plans, and 56% of payment plans introduced new treatments for that particular patient.¶

• Staff Training and Supplemental Support: Hands-on demos, product tutorials, group webinars, FAQs, talk tracks, and more—all available to your full staff.

• Digital Assets and Office Materials: Ready to send emails, website assets, marketing messages, and signage to amplify awareness.

Find helpful information about Allē Payment Plans at business.alle.com/payment-plans and much more on BrandBox at allerganbrandbox.com.

For your patients

• Brochure: Supplemental education for patients to read in the office or take home with them.

• Website: Online destination (alle.com/payment-plans) with answers to common questions, and a link to apply.

• Allē App: Mobile application for patients to apply for Allē Payment Plans and see their approved balance in Allē Wallet.

For any questions about Allē, please reach out to your Allergan Aesthetics sales representative, or contact Allē Support at 888.912.1572 Monday–Friday from 8 AM–6 PM CT.

If you experience issues with Cherry payment plans or the application process, please contact Cherry Support at 888.839.7171 Monday–Friday from 8 AM–8 PM CT, Saturday from 8 AM–5 PM CT, or email support@withcherry.com.

* Internal Cherry Data.

† For eligible Allergan Aesthetics treatments only.

‡ You will be required to accept Cherry’s Terms and Conditions.

§ Payouts in full for eligible Allergan Aesthetics products and treatments only. All other services are subject to standard Cherry rates.

Payment options through Cherry Technologies, Inc. are issued by the following lending partners: https://withcherry.com/lending-partners/. Term length, loan amount, 0% APR and other promotional rates are subject to eligibility. See www.withcherry.com/terms for details.

II Internal Data, 2024.

¶ Results from first 170 treatments in pilot practices. Allē Data, November 18, 2023 - March 18, 2024. © 2025 Cherry Technologies Inc. All rights reserved. Payment options through Cherry Technologies Inc. are issued by Cross River Bank, member FDIC. © 2025 AbbVie. All rights reserved. Allē and its design are service marks of Allergan, Inc., an AbbVie company. Allergan Aesthetics reserves the right to alter or cancel the program with no advance notice or obligation. PRT164753-v4 01/25

Friday, March 14, 2025

Day 2 - Track 1 Scientific Sessions – Main Ballroom

7.30 am Breakfast with Exhibitors

8:00 - 10:00 BIOSTIMULATORY AESTHETICS

Moderator: Saami Khalifian, MD

8:00 - 8:15 Optimizing and Enhancing BBL Procedures with PLLA Both Non-Surgically and Surgically – Raffi Hovsepian, MD

8:15 - 8:30 Platelet Derived Skin Treatments – Saranya Wyles, MD

8:30 - 8:45 The New Era of Rejuvenation: Regenerative Therapies for Healthy Aging – Amy Lynn, RN

8:45 - 9:00 Autologous Blood Platelet Therapies as a Bio Filler (PRF & albumin-PRF) – Anil Rajani, MD

9:00 - 9:15 Biostimulators Most Up To Date Applications – Saami Khalifian, MD

9:15 - 9:30 Exosomes – Where Is The Data and What Are Current and Potential Future Applications? – Saranya Wyles, MD

9:30 - 10:00 PANEL With Live Q&A – Raffi Hovsepian, MD, Saami Khalifian, MD, Amy Lynn, RN, Anil Rajani, MD, Saranya Wyles, MD

10:00 - 10:30 Coffee Break with Exhibitors

10:30 - 12:00 LIPS, CHIN, JAWLINE and NECKS: Surgical and Non-Surgical Approaches

Moderator: John Vartanian, MD

10:30 - 10:45 Enhancing the Chin Aesthetics: Fillers vs Implants – John Vartanian, MD

10:45 - 11:00 Facial Reshaping with Injectables – Keith Marcus, MD

11:00 - 11:15 Lips & Lipstick. What’s New? – Julie Woodward, MD

11:15 - 11:30 Gliding Under The Surface: The Power of Microcannula In The Lower Third of The Face – George Baxter-Holder, DNP

11:30 - 11:45 Non-Surgical Rejuvenation of the Neck – Injectables, Devices, and Carboxytherapy – Sharon Stewart, PA-C

11:45 - 12:00 Demystifying The Ozempic Face – It’s Not What You Think - Steve Dayan, MD

12:00 - 12:15 Contour and Harmony: Innovative Strategies in Lip, Jawline, and Neck Enhancement – Charles Boyd, MD

12:15 - 12:30 PANEL With Live Q&A – George Baxter-Holder, DNP, Charles Boyd, MD, Steve Dayan, MD, Keith Marcus, MD, Sharon Stewart PA-C, John Vartanian, MD, Julie Woodward, MD

12:30 - 1:30 Lunch with Exhibitors

InMode Aesthetics Lunch & Learn, Incorporating Morpheus8 In My Clinic – Lisa Espinoza, MD Live Demo and Discussion – Sponsored Workshop, Palm Room

1:30 - 2:00 KEYNOTE SPEAKER: – Artificial Intelligence in Medical Aesthetics – From The HYPE To The HOW Lauren Abney, AI Business Strategist, Google Introduction by: Kian Karimi, MD

2:00 - 2:30 SPECIAL LECTURE: The Importance of Dental Aesthetics To Your Patients

– Laurence Rifkin, DDS & Dan Grauer, DDS

2:30 - 3:00 Coffee Break with Exhibitors

3:00 - 6:00 Leading Aesthetic Techniques – Live Demos – Non-CME Moderator: Kian Karimi, MD

3:00 - 3:45 Botox for Platysmal Bands – Sabrina Fabi, MD

3:45 - 4:15 Temple Enhancement with Voluma – Charles Boyd, MD

4:15 - 5:15 THE ART OF REVERSAL SPECIAL SESSION – Combining EZGEL and Ultrasound Guided Dissolving for Optimal Aesthetic Results

– Shanna Concepcion, RN, Kian Karimi MD, Amy Lynn, RN, Anil Rajani, MD & Steven Sorr, NMD

5:15 - 6:00 Ask Me Anything About Aesthetics! Burning Questions To Ask Our Faculty.

– George Baxter-Holder, DNP, Lisa Espinoza, MD, Sabrina Fabi, MD, Saami Khalifian, MD, Keith Marcus, MD, Anil Rajani, MD

6:00 - 7:30 Innovations in Aesthetics Reception – Sponsored by Allergan

Friday March 14, 2025

Day 2 - Track 2 Business & Marketing Sessions – II Posto Room

7:30 am Breakfast with Exhibitors

8:00 - 10:00 People, People, People: The Challenges Aesthetic Practices Face More Than Ever

8:00 - 8:05 Goals of the Session – Josh DeBlasio

8:05 - 8:25 Purpose in Practice: Holistic Leadership by Aligning Purpose, People and Performance – Shawn Allen, MD

8:25 - 8:40 Bridging Leadership and Impact: The ROI of Leadership Development – Gina Goick Mangum

8:40 - 9:00 Identifying High Performers: A Modern Approach to Interviewing Candidates – Brian Hayes

9:00 - 9:20 The Art of the Hire: Finding Talent That Matches Your Vision – Katie Martin, PA-C

9:20 - 9:40 Should I Kick Them to the Curb or Ignite the Spark in a Slumping Superstar – Robin Ntoh

9:40 - 10:00 Strategic Employee Retention Begins with You – Kirstie Jackson

10:00 - 10:30 Coffee Break

10:30 - 10:50 How Should I Pay My Team? Ideas and Examples of Compensation Structures to Drive the Right Behaviors – Amy Anderson, MBA

10:50 - 11:10 Perks with a Purpose: Introducing Employee Benefits that Go Beyond the Usual and Support Well-Being, Growth, and Work-Life Balance – Leslie Tracy

11:10 - 11:30 How to Avoid Legal Nightmares When it Comes to Staffing – Sara Shikhman, Esq.

11:30 - 12:30 Open Discussion: Compensation Plans, Retention Strategies and Hiring Done Right! – Panelists and Audience Interaction

12:30 - 1:30 Lunch with Exhibitors

InMode Aesthetics Lunch & Learn, Incorporating Morpheus8 In My Clinic – Lisa Espinoza, MD Live Demo and Discussion – Sponsored Workshop, Palm Room

1:30 - 5:00 Mastering Digital Marketing in 2025

1:30 - 1:35 Goals of the Session – Josh DeBlasio

1:35 - 1:55 AI in your Clinic. Everything you Need to Know to Maximize 2025 – Jared Rohrer

1:55 - 2:10 Creating the Ultimate Online Presence for Your Aesthetics Practice – Michael Antosy

2:10 - 2:30 We Are Out of Ideas: Giving Your Social Media Strategy a Boost with Unique Ideas to Drive Engagement – Neil Foster

2:30 - 3:00 Break with Exhibitors

3:00 - 3:20 Attracting High Profile Influencers Without Spending a Dime – Daniel Barrett, MD

3:20 - 3:40 Perfecting My Website: What Every Site Must Include and How to Measure Success! – Jared Rohrer

3:40 - 4:00 Online Reviews and Digital Marketing: Legal Essentials to Keep the Attorneys Away – Sara Shikhman, Esq.

4:00 - 4:20 Tapping into TikTok – Daniel Barrett, MD

4:20 - 4:40 SEO and SEM: Improve Your Ranks Today with These Easy, Cost Effective Steps – Neil Foster

4:40 - 5:00 Open Discussion: The Best Ways to Spend and Track in Today’s Market – Panelists and Audience Interaction

LEARN WITH US AND EXPLORE THE

AESTHETIC MEDICINE

INSIGHTS FROM INTERNATIONALLY RECOGNIZED INDUSTRY EXPERTS

The Art of Reversal: Combining ezGEL and Ultrasound-Guided Dissolving for Safer Aesthetic Results.

Master the art of ezGEL restoration, a 100% natural biostimulator that enhances collagen, restores volume, and improves skin quality. Combine it with the precision of ultrasound-guided dissolving to safely remove unwanted ﬁllers, achieving more natural and effective aesthetic corrections. REVERSE. RESTORE. REJUVENATE.

Friday, March 14 4:15 PM – 5:15 PM Main Ballroom

HOSTED BY

Kian Karimi MD, FACS, Anil Rajani, MD, Amy Lynn, RN, Shanna Concepcion, RN, CANS and Steven Sorr, NMD

Advanced ezPRF & ezGEL Techniques for Regenerative Biostimulation

Take your practice to the next level with ezPRF and ezGEL techniques, 100% natural solutions for collagen stimulation, volume restoration, and long-lasting tissue regeneration. Offer your patients a natural approach to skin rejuvenation for superior results. PUSH BOUNDARIES. PERFECT YOUR CRAFT. TRANSFORM RESULTS.

Saturday, March 15 11:30 AM – 12:30 PM

HOSTED BY

Shanna Concepcion, RN, CANS

March 14, 2025

Day 2 - Track 3 New & Current Trends in Aesthetics – Burton Room

7:30 - 8:00 Breakfast with Exhibitors

8:00 - 10:00 SEXUAL WELLNESS AND REJUVENATION

Moderator: Steven Sorr, NMD

8:00 - 8:20 P shots and O shots – How to Implement in Your Practice and Techniques for Success – Joelle Lieman, MD

8:20 - 8:40 Hormones for Sexual Health, Libido, and Wellness – Steven Sorr, NMD

8:40 - 9:00

Testosterone in Women’s Health – An Integrative Approach – Sarah Dalhoumi, MD

9:00 - 9:20 Hyaluronic Acid Fillers to the Penis – How and Why? – Lanna Cheuck, DO

9:20 - 10:00 PANEL With Live Q&A – Lanna Cheuck, DO, Sarah Dalhoumi, MD, Joelle Lieman, MD & Steven Sorr, NMD

9:30 - 10:00 Coffee Break with Exhibitors

10:00 - 10:30 NOVEL & INNOVATIVE AESTHETIC TREATMENTS

Moderator: Francine Young, RN, MEP-C

10:30 - 10:50 Cannabidiol for the Treatment of Acne Vulgaris and For Skin Rejuvenation – Francine Young, RN, MEP-C

10:50 - 11:10 New Technology to Enhance Advanced PDO Thread Cases– Scott Callahan, PA-C

11:10 - 11:30 What Is In The Neurotoxin, Filler and Biostimulator Pipeline? – John Joseph, MD

11:30 - 12:00 PANEL With Live Q&A – Scott Callahan, PA-C, John Joseph, MD, Francine Young, RN, MEP-C

12:00 - 1:30 Lunch with Exhibitors

Saturday, March 15, 2025

Day 3 - Track 1 – Main Ballroom

LIVE IMMERSION CLINICS

TWO SESSIONS - MORNING & AFTERNOON

7:30 - 8:00 Breakfast with Exhibitors

10:30 - 12:30 MORNING LIVE IMMERSION

10:30 - 12:30 Fillers, Injectables, and Biostimulators - Rotating Live Model Demonstrations

1. Upper Third Rejuvenation with Fillers and Neurotoxin – Lisa Espinoza, MD

2. Management of Delicate Under Eye Tissues for Maximum Results – Sandy Zhang-Nunes, MD

3. Best Approaches to Lip Augmentation and Perioral Rejuvenation – Ben Talei, MD

4. Neurotoxins, Fillers, and Biostimulators for Lower Third Face and Neck Improvement – Julie Bass Kaplan, FNP

5. Biostimulators To The Face – Amy Lynn, RN

6. Crepe Cake Technique for Under Eyes, Including Exosomes and PDO Threads – Francine Young, RN, MEP-C

12:30 - 1:30 Lunch with Exhibitors

1:30 - 3:30 AFTERNOON LIVE IMMERSION

1:30 - 3:30 Fillers, Injectables, and Biostimulators - Rotating Live Model Demonstrations

1. Upper Third Rejuvenation with Fillers and Neurotoxin – Lisa Espinoza, MD

2. Jawline Improvement in A Male Patient Using a Blended Technique – Saami Khalifian, MD

3. Best Approaches to Lip Augmentation and Perioral Rejuvenation – Keith Marcus, MD

4. Neurotoxins, Fillers, and Biostimulators for Lower Third Face and Neck Improvement – Julie Bass Kaplan, FNP

5. Autologous Blood Platelets & Threads – Shanna Concepcion, RN

6. Crepe Cake Technique for Under Eyes, Including Exosomes and PDO Threads – Francine Young, RN, MEP-C

6:30 - 8:30 Join the Party! – LA-MCA Casino Royale Theme Party!!! Co-Sponsored by CosmoFrance

Saturday, March 15, 2025

Day 3 - Track 2 Business & Marketing Sessions – II Posto Room

7:30 am Breakfast with Exhibitors

8:00 - 5:00 BUSINESS OF AESTHETICS - Driving Revenue When Times Are Tough

8:15 - 8:45 Internal Marketing: What It Means & To Do It. Real Life Examples from a Successful Practice Business of Aesthetics. Driving Revenue when Times are Tough

8:00 - 8:05 Goals of the Session – Josh DeBlasio

8:05 - 8:20 Clinical Studies: The Difference Between a Legit Clinical Study and Propaganda – John Joseph, MD

8:20 - 8:40 How Much Should I Charge: Pricing Strategies to Drive Revenue, Differentiation and Results – Josh DeBlasio

8:40 - 9:00 Where is Your Money Going? Managing Cash Flow in Your Practice – Christin Trujillo

9:00 - 9:20 The Art of the Consultation: How to Increase Patient Satisfaction and Grow Sales – Zena Gabriel, MD

9:20 - 9:40 Big Business Strategies for Aesthetic Practices: Insights From Fortune 500 Companies That Small Business Should Apply – Alex Grazier

9:40 - 10:00 Top 5 Financial Mistakes Keeping You From Higher Profits – Christin Trujillo

10:00 - 10:30 Break with Exhibitors

10:30 - 10:50 More than Cash: The Best Non-Financial KPI’s to Track – Kirstie Jackson

10:50 - 11:10 Beyond the Glow: Why Skincare Recommendations Matter Clinically and Financially – Katie Martin, PA-C

11:10 - 11:30 Private Equity: What Every Practice Needs To Know, Whether They Are Selling Or Not – Josh DeBlasio

11:30 - 12:30 Open Discussion – Differentiating and Making Money In Today’s Competitive Environment – Panelists and Audience Interaction

12:30 - 1:30 Lunch with Exhibitors

1:30 - 5:00 Aesthetic Medicine: Sharpening Your Business Skills to Benefit Your Practice and your Patients

1:30 - 1:35 Goals of the Session – Josh DeBlasio

1:35 - 1:55 10 Hidden Costs Crushing Your Business Profits – Robin Ntoh

1:55 - 2:10 Converting Leads: The Lost Art of Getting Patients Scheduled and How to Measure Success! – Amy Anderson, MBA

2:10 - 2:30 From Patients to Lifelong Fans: The Patient Loyalty Formula for 7-Figure Recurring Revenue – Adrienne Easterling, PA-C

2:30 - 3:00 Break with Exhibitors

3:00 - 3:20 Scaling Up Your Aesthetic Business: The Why and How to Take it to the Next Level – Edwin Williams, MD

3:20 - 3:40 A Man, a Puppy and a Pair of Sunglasses: Lesson In Creating Lifetime Patient Loyalty – Brian Hayes

3:40 - 4:00 Tales From an Attorney: What Makes Me Cringe-and How to Prevent it in Your Practice – Sara Shikhman, Esq.

4:00 - 4:20 Empowering Growth: The Transformative Impact of Collaborative Training, Mentorship & Co-Op Programs – Cheryl Wiseman, BSN

4:20 - 5:00 Open Discussion: Mistakes I Made When Building My Practice That You Should Avoid – Panelists and Audience Interaction

Saturday, March 15, 2025

Day 3 - Track 3 MCA Masters Workshops – Burton Room

MCA MASTERS WORKSHOPS WITH

Burton Room

8:00 - 10:00 The Next Frontier in Facial Biostimulators –MesoSynergy Skin Priming

Presenters: Shino Bay Aguilera, DO & Morgan Renfro, RN

Discover “MesoSynergy,” an innovative approach that primes the skin before collagen biostimulators for optimal bioregenerative success. By nourishing aging fibroblasts with vital nutrition, hydration, and protection, you’ll learn how proper preparation supercharges biostimulation results. Walk away with practical tips on achieving natural, enduring facial rejuvenation with advanced biostimulator concepts and techniques.

Day 3 - Track 3 MCA Workshops – Beechwood Room

MCA MASTERS WORKSHOPS WITH LIVE DEMONSTRATION

Beechwood Room

8:00 - 10:00 PDO Threads: A 360° Approach to Full Facial Rejuvenation

Presenters: Kian Karimi, MD & Francine Young, RN, MEP-C

Uncover the transformative potential of PDO threads in this comprehensive live demonstration and didactic session. Learn how midface thread lifts, combined with dermal fillers and neuromodulators, deliver harmonious, lifted contours.

Layered onto this are skin-boosting techniques to enhance skin radiance and glow, to achieve a 360° perspective on full-face rejuvenation strategies that keep patients coming back.

Beechwood Room

4:00 - 6:00 Advanced Lip Techniques

Presenters: Ben Talei, MD & Taylor Szupiany, PA-C

Explore cutting-edge lip rejuvenation and shaping methods that will help you achieve unparalleled clinical outcomes for your patients. Delve into the nuances of lip proportion, contour, and subtle volumization techniques that yield natural yet striking results. Elevate your expertise with fine-tuned approaches that balance aesthetic ideals and patient satisfaction, with a deep dive into advanced anatomical paradigms.

MCA Masters Workshops are an additional fee of $950 each attendee and non-CME

Francine Young, RN, MEP-C

Kian Karimi, MD

Ben Talei, MD Taylor Szupiany, PA-C

THE MOST-AWARDED LIP FILLER

U.S. BEAUTY PUBLICATIONS1

Actual patient. Individual results may vary.

References: 1. Data on file. Galderma Laboratories, L.P., 2024.

IMPORTANT SAFETY INFORMATION

Indication: Restylane® Kysse is indicated for injection into the lips for lip augmentation and for correction of upper perioral rhytids in patients over the age of 21.

Restylane Kysse contains traces of gram-positive bacterial protein and is contraindicated for patients with allergies to such material or for patients with severe allergies that have required in- hospital treatment. Restylane Kysse should not be used by patients with bleeding disorders, with hypersensitivity to amide-type local anesthetics, such as lidocaine, or by women who are pregnant or breastfeeding.

Use of Restylane Kysse at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete. The most commonly observed side effects are swelling, tenderness, bruising, pain, and redness at the injection site. These are typically mild in severity and usually resolve within 7 days after treatment.

Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis and scarring at the injection site. Do not implant into blood vessels. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.

Treatment volume should be limited to 1.5 mL per lip per treatment and 1.0 mL for upper perioral rhytid correction, as greater amounts significantly increase moderate and severe injection site reactions. The safety or effectiveness of treatment in areas other than lips and upper perioral rhytids has not been established in controlled clinical studies.

Restylane Kysse is only available through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.

Saturday, March 15, 2025

Day 3 - Track 3 MCA Masters Workshops – Palm Room

MCA MASTERS WORKSHOPS WITH LIVE DEMONSTRATION

Palm Room

8:00 - 10:00 Mastering the Upper Face: Temple, Forehead, Peri-Ocular (Using Fillers & Biostimulators)

Presenters: Jill Hessler, MD & Amy Faircloth, RN

Refine your approach to the upper face with advanced insights on temples, forehead, and the delicate peri-ocular zone. Learn how the interplay of light, shadow, and precise injection techniques can subtly transform eyelid and periocular aesthetics. In this session, you will learn essential strategies for selecting the right products in danger zones—ensuring safer, more beautiful outcomes, and how the periocular region influences overall facial appearance.

Palm Room

4:00 - 6:00   Peri-Ocular Rejuvenation: Enhancing Your Treatment Arsenal

Presenters: Julie Woodward, MD & Julie Bass-Kaplan, FNP

The peri-ocular region can be both captivating and complex. In this workshop, two leading experts demystify the anatomy and demonstrate evidence-based approaches— ranging from injectables (PRP/PRF/PDGF/dermal fillers) to energy devices to surgery and dissolving protocols. Gain confidence in reducing complications while delivering natural, refreshed results that respect each patient’s unique contours.

Day 3 - Track 3 MCA Masters Workshops – Linden Room

Linden Room

8:00 - 10:00 Sexual Health: Penile & Vaginal Rejuvenation (with Video Demonstration)

Presenters: Joelle Lieman, MD & Lanna Cheuck, DO

Delve into the fast-evolving realm of sexual health aesthetics. Learn practical injection techniques (HA fillers, PRP, PRF) that enhance both form and function for the penis and vagina. Explore the latest best practices, safety measures, and emerging applications that can expand your service offerings and patient results.

Linden Room

4:00 - 6:00  Non-Surgical Liquid Rhinoplasty

Presenters: Charles Boyd, MD & John Vartanian, MD

Elevate your rhinoplasty repertoire with advanced non-surgical techniques. This session unpacks critical anatomical considerations, product selection, and complication avoidance. Watch a live demonstration to see how subtle injections can create dramatic improvements—offering patients a less invasive path to facial harmony.

MCA Masters Workshops are an additional fee of $950 each attendee and non-CME

Amy Faircloth, RN

Lanna Cheuck, DO

Julie Bass-Kaplan, FNP

John Vartanian, MD

Jill Hessler, MD

Joelle Lieman, MD

Julie Woodward, MD

Charles Boyd, MD

Sunday, March 16, 2025

Day 4 - Track 1 MCA CADAVER WORKSHOP – Main Ballroom

MCA CADAVER HANDS-ON WORKSHOP

Course Director: Kian Karimi, MD

Faculty: Julie Bass Kaplan, FNP, Saami Khalifian, MD, Steven Sorr, NMD, John Vartanian, MD & Sandy Zhang-Nunes, MD, Francine Young, RN

7:15 am Breakfast with Exhibitors

Advanced Fillers, Injectables, PDO Threads & Ultrasound Guided Injection Hands-On Cadaver Dissection Workshop

8:00 - 1: 30 Hands-On Learning Experience

• Pertinent Anatomy for the Injector and Identifying Danger Areas

• Neuromodulator Techniques

• Periocular (Tear Trough, Temple) Anatomy and Injection Techniques – Needle and Cannula

• Anatomy of Midface Fat Compartments and Filler Injection Techniques – Needle and Cannula

• PDO Threads Techniques (Mesh and Lifting Techniques)

• Surgical Faculty at Each Station to Guide Attendees Through Hands-On Injections

• Fillers and Threads Will Be Provided

• Lip Injection Techniques

• Ultrasound Guided Injection

MCA Masters Workshops are an additional fee of $950 each attendee and non-CME LA-MCA Cadaver Course workshop is not included in registration fee and Is $2995 each per attendee

Sunday, March 16, 2025

Day 4 - Track 3 – Palm Room

MCA MASTERS WORKSHOPS WITH LIVE DEMONSTRATION

Palm Room

8:00 - 10:00 MidFace Workshop: Skin Boosting & Biostimulators Balancing

Presenters: Shanna Concepcion, RN & Sherly Soleiman, MD

Dive into advanced midface rejuvenation as two industry leaders showcase panfacial injections, including cheek and chin refinement, tear trough correction, and skin quality treatments. Explore how combining skin boosters and biostimulators can amplify patient results. Leave with new techniques to streamline treatments and expand your aesthetic offerings.

Palm Room

10:30 - 12:30  Biostimulators: Booty

Presenters: Amy Faircloth, RN & Morgan Renfro, RN

Enhancement of the buttock remains of high interest to patients, particularly in the era of GLP-1s. Biostimulators remain an excellent option for non-surgical buttock augmentation and emerging evidence has demonstrated that new paradigms may lead to enhanced results. Learn the science behind the use of dermal fillers and biostimulators for the gluteal region, reconstitution best practices, and safe injection protocols that sculpt and rejuvenate. Discover complication prevention strategies to ensure consistently pleasing, confidence-building outcomes.

Day 4 - Track 3 – Linden Room

Linden Room

8:00 - 10:00 Jawline & Neck: Including Skin Boosters & Topicals

Presenters: John Vartanian, MD & George Baxter Holder, DNP

Refine the jawline and neck with a strategic blend of volumization, contouring, and collagen stimulation. This session highlights anatomy-based techniques, innovative product use, and the role of topical and skin-boosting treatments. Gain valuable pearls to ensure a sculpted, natural look for every patient while simultaneously improving skin quality and tone.

Linden Room

10:30 - 12:30  Facial Neuromodulators Techniques

Presenters: Shanna Concepcion, RN & Laurence Rifkin, DDS

Stay ahead of the game with forward-thinking neuromodulator approaches that address both aesthetic and therapeutic concerns. Master upper-face, lower face, and neck treatment techniques and explore novel toxin applications for pores, acne, rosacea, and more. Elevate your expertise with comprehensive techniques that keep your patients looking and feeling their best.

MCA Masters Workshops are an additional fee of $950 each attendee and non-CME

Sherly Soleiman, MD

George Baxter Holder, DNP

Laurence Rifkin, DDS

Shanna, Concepcion, RN

John Vartanian, MD

Amy Faircloth, RN Morgan Renfro, RN Shanna Concepcion, RN

The #1 regenerative injectable biostimulator1-4

6 MONTHS AFTER 6 MONTHS AFTER

GABRIELA, 36 | 3 VIALS

Actual patient. Treated with Sculptra® 8-mL reconstitution injected in the broader cheek area. Individual results may vary.

Important Safety Information

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

REFERENCES: 1. Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922. 2. Data on file. GLI.04.US.SL.020 clinical study report. Dallas, TX: Galderma Laboratories, L.P. 2023. 3. Bohnert K, Dorizas A, Lorenc P, Sadick NS. Randomized, controlled, multicentered, double-blind investigation of injectable poly-L-lactic acid for improving skin quality. Dermatol Surg. 2019;45:718–724. 4. Bio-stimulators net sales market share as of April 2024.

DEFINITELY DYSPORT

Dysport® is your trusted partner for authentic beauty. See what Dysport can do for your patients.

Actual patient. Individual results may vary.

98%

of users

hours 24

months

98% of users say they would get Dysport again, while 97% of users say their results look natural.1*

You may see results as early as 1 day after treatment, with typical results within 2-3 days.2,3†

Improvements to frown lines and overall results can last up to 5 months.3-5‡

*Users=clinical trial subjects. Subject-reported at 12 months (N=120) after two treatments six months apart in a phase IV, multicenter, prospective study.

†Based on subject self-assessment. The onset of response at day 1 was 15% (16/105) in GL-1 and 33% (65/200) in GL-3. In the DREAM study, the onset of response at day 1 was 33% (66/200). The median time to onset of response was 3 days in GL-1 (55/105; 52%) and GL-2 (36/71; 51%), and 2 days in GL-3 (110/200; 55%).

‡GL-1 and GL-3 evaluated subjects for at least 150 days following treatment. Based on a ≥1-Grade GLSS improvement from baseline utilizing data from two double-blinded, randomized, placebo-controlled pivotal studies (GL-1, GL-3) in a post-hoc analysis.

REFERENCES: 1. Schlessinger J, et al. A multicenter study to evaluate subject satisfaction with two treatments of abobotulinumtoxinA a year in the glabellar lines. Dermatol Surg. 2021;47(4):504-509. 2. Rubin MG, et al. The efficacy and safety of a new U.S. botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8(5):439-444. 3. Monheit GD, et al. Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatol Surg. 2020;46(1):61-69. 4. Brandt F, et al. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35(12):1893-1901. 5. Data on file. MA-35497. Post Hoc Analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017.

IMPORTANT INFORMATION ABOUT

Dysport® (DIS-port) (abobotulinumtoxinA) for Injection

BRIEF SUMMARY

This summary contains important information about Dysport (DIS-port) for injection. Read this information carefully before using Dysport. Ask your doctor if you do not understand any of this information or if you want to know more about Dysport. For full Prescribing Information and Medication Guide, please see the package insert.

What is Dysport?

Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Important Safety Information

WARNING: DISTANT SPREAD OF TOXIN EFFECT

In some cases, the effects of Dysport and all botulinum toxin products may affect areas of the body away from the injection site. Symptoms can happen hours to weeks after injection and may include swallowing and breathing problems, loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, or loss of bladder control. Swallowing and breathing problems can be life threatening and there have been reports of death. You are at the highest risk if these problems are pre-existing before injection. These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Who should not take Dysport?

Do not take Dysport if you:

• are allergic to Dysport or any of its ingredients. See the end of this Medication Guide for a list of ingredients in Dysport

• are allergic to cow’s milk protein

• had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA)

• have a skin infection at the planned injection site

• Under 18 years of age

Pregnant or breastfeeding

What additional warnings and precautions should I know about Dysport?

• The dose of Dysport is not the same as the dose of any other botulinum toxin product and cannot be compared to the dose of any other botulinum toxin product you may have used.

• Dysport may not be right for you if you have surgical changes to your face, very weak muscles in the treatment area, your face looks very different from side to side, the injection site is inflamed, you have droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, or if your wrinkles can’t be smoothed by spreading them apart.

• Tell your doctor about all of your medical conditions, especially if you have a disease that affects muscles and nerves (such as amyotrophic lateral sclerosis [ALS or Lou Gehrig’s disease], myasthenia gravis, or Lambert-Eaton syndrome), allergies to any botulinum toxin product or had any side effect from any botulinum toxin product in the past, a breathing problem (such as asthma or emphysema), swallowing problems, bleeding problems, diabetes, or a slow heart beat or other problem with your heart rate or rhythm, plans to have surgery, had surgery on your face, have weakness in or near your muscles being treated, drooping eyelids, any other change in the way your face normally looks, or are pregnant or breastfeeding or planning to become pregnant or breastfeed Patients with swallowing or breathing difficulties or a disease that affects muscles and nerves may have a higher risk of serious side effects, including severe swallowing and breathing problems, after treatment with Dysport

• Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using Dysport with certain other medicines may cause serious side effects. Do not start any new medicines while taking Dysport without talking to your doctor first.

• Especially tell your doctor if you: have received any other botulinum toxin product, such as Myobloc® (rimabotulinumtoxinB), Botox® (onabotulinumtoxinA), or Xeomin® (incobotulinumtoxinA), in the last four months or any in the past (be sure your doctor knows exactly which product you received, have recently received an antibiotic by injection, take muscle relaxants, take an allergy or cold medicine, or take a sleep medicine.

What are the side effects of Dysport?

The most common side effects of Dysport include nose and throat irritation, injection site pain, upper respiratory infection, blood in urine, headache, injection site reaction, eyelid swelling, eyelid drooping, sinus infection, and nausea.

These are not all the possible side effects of Dysport. Call your doctor for medical advice about side effects.

You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

This Brief Summary summarizes the most important information about Dysport. If you would like more information, talk with your doctor.

What are the ingredients of Dysport?

Active ingredient: (botulinum toxin Type A)

Inactive ingredients: human albumin and lactose. Dysport may contain cow’s milk protein. Where should I go for more information about Dysport?

Talk to your doctor.

• Visit www.DYSPORTUSA.com.

GALDERMA LABORATORIES, L.P.

Dallas, Texas 75201 USA

Revised: September 2023

The Dysport trademark is used under license. All trademarks are the property of their respective owners. US-DYS-2500007

The Power of Platelet-Derived Exosomes

Driven by 15 years of scientific innovation

Renewosome™ Technology harnesses platelet-derived exosomes to support the skin’s natural renewal process, delivering targetted benefits for visible improvements in texture, tone, and vitality.

Visible reduction in wrinkles

Scan to get in touch with us.

Visible reduction in redness

THE ULTIMATE RESET FOR DRY SKIN

DermProtect

Barrier Defense™

• Resets and regulates skin’s natural 24-hour cycle

• Repairs skin barrier function

• Supports a balanced microbiome

• Delivers immediate and long-term moisturization

• Soothes, calms, and revitalizes dry skin

Own the vial

Treatment in all 4 areas— from a single 100 Unit vial1

For the temporary improvement in the appearance of moderate to severe platysma bands (26U, 31U, or 36U), forehead lines (20U), lateral canthal lines (24U), and glabellar lines (20U) in adults.1

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications

BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

- Moderate to severe lateral canthal lines associated with orbicularis oculi activity

- Moderate to severe forehead lines associated with frontalis activity

- Moderate to severe platysma bands associated with platysma muscle activity

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation

WARNINGS AND PRECAUTIONS

Lack of Equivalency Between Botulinum Toxin Products

The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. BOTOX® Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Please see additional Important Safety Information on following page. To

IMPORTANT SAFETY INFORMATION (continued)

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX® Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including preexisting cardiovascular disease. Use caution when administering to patients with preexisting cardiovascular disease.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders

Patients with neuromuscular disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions). Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties

Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

Preexisting Conditions at the Injection Site

Use caution when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic

There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases

Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

The safety profile of BOTOX® Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX® Cosmetic for other indications.

DRUG INTERACTIONS

Coadministration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see Brief Summary of full Prescribing Information, including Boxed Warning, on the following pages.

For more information on BOTOX® Cosmetic, scan to see full Prescribing Information, including Boxed Warning and Medication Guide.

Reference: 1. BOTOX® Cosmetic Prescribing Information, October 2024.

BOTOX®

Cosmetic

(onabotulinumtoxinA) for

injection, for intramuscular, intradetrusor, or intradermal

use

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. [see Warnings and Precautions]

INDICATIONS AND USAGE

BOTOX Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:

• moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity

• moderate to severe lateral canthal lines associated with orbicularis oculi activity

• moderate to severe forehead lines associated with frontalis muscle activity

• moderate to severe platysma bands associated with platysma muscle activity

CONTRAINDICATIONS

Known Hypersensitivity to Botulinum Toxin

BOTOX Cosmetic is contraindicated in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation [see Warnings and Precautions]

Infection at the Injection Site(s)

BOTOX Cosmetic is contraindicated in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

Lack of Equivalency Between Botulinum Toxin Products

The potency Units of BOTOX Cosmetic are specific to the preparation and assay method utilized. BOTOX Cosmetic is not equivalent to other preparations of botulinum toxin products, and therefore, Units of biological activity of BOTOX Cosmetic cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect

Postmarketing safety data from BOTOX Cosmetic and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, and particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia and spasticity. Advise patients or caregivers to seek immediate medical care if swallowing, speech or respiratory disorders occur.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX/BOTOX Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines), or 100 Units (for severe primary axillary hyperhidrosis) have been reported.

No definitive serious adverse event reports of distant spread of toxin effect associated with BOTOX for blepharospasm at the recommended dose (30 Units and below), strabismus, or chronic migraine at the labeled doses have been reported.

Serious Adverse Reactions with Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX. The safety and effectiveness of BOTOX for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea. If such a reaction occurs, discontinue further injection of BOTOX Cosmetic and immediately institute appropriate medical therapy. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent, and consequently the causal agent cannot be reliably determined.

Cardiovascular System

There have been reports following administration of BOTOX/BOTOX Cosmetic of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease. Increased Risk of Clinically Significant Effects with Pre-Existing Neuromuscular Disorders

Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise from onabotulinumtoxinA [see Warnings and Precautions]. Monitor individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) when given botulinum toxin.

Dysphagia and Breathing Difficulties

Treatment with BOTOX and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing [see Warnings and Precautions] Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.

Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing difficulties, including respiratory failure.

Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscle for the treatment of cervical dystonia have been reported to be at greater risk for dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Injections into the levator scapulae may be associated with an increased risk of upper respiratory infection and dysphagia.

Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin [see Warnings and Precautions]

Pre-existing Conditions at the Injection Site

Use caution when BOTOX Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s), ptosis, or when excessive weakness or atrophy is present in the targeted muscle(s).

Corneal Exposure and Ulceration in Patients Treated with BOTOX for Blepharospasm

Reduced blinking from injection of botulinum toxin products in or near the orbicularis oculi muscle can lead to corneal exposure, persistent corneal epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders.

Employ vigorous treatment of any corneal epithelial defect. This may require protective drops, ointment, therapeutic soft contact lenses, or closure of the eye by patching or other means.

Dry Eye in Patients Treated with BOTOX Cosmetic

There have been reports of dry eye associated with BOTOX Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (e.g., eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist [see Warnings and Precautions]

Spatial Disorientation, Double Vision or Past-Pointing in Patients Treated for Strabismus

Inducing paralysis in one or more extraocular muscles may produce spatial disorientation, double vision or past pointing. Covering the affected eye may alleviate these symptoms.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of CreutzfeldtJakob disease (CJD), which would also be considered remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

The following adverse reactions to BOTOX Cosmetic (onabotulinumtoxinA) for injection are discussed in greater detail in other sections of the labeling:

• Spread of Toxin Effects [see Warnings and Precautions]

• Hypersensitivity [see Contraindications and Warnings and Precautions]

• Dysphagia and Breathing Difficulties [see Warnings and Precautions]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

BOTOX and BOTOX Cosmetic contain the same active ingredient in the same formulation, but have different labeled Indications and Usage. Therefore, adverse events observed with the use of BOTOX also have the potential to be observed with the use of BOTOX Cosmetic.

In general, adverse reactions occur within the first week following injection of BOTOX Cosmetic and while in many cases are transient, may have a duration of several months or longer. Localized pain, infection, inflammation, tenderness, swelling, erythema, and/or bleeding/bruising may be associated with the injection. Needle-related pain and/or anxiety may result in vasovagal responses (including e.g., syncope, hypotension), which may require appropriate medical therapy.

PROFESSIONAL BRIEF SUMMARY CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

Local weakness of the injected muscle(s) represents the expected pharmacological action of botulinum toxin. However, weakness of nearby muscles may also occur due to spread of toxin [see Warnings and Precautions]

Glabellar Lines

Table 1 lists selected adverse reactions reported by ≥1% of BOTOX Cosmetic treated subjects (N=405) aged 18 to 75 who were evaluated in the randomized, placebo-controlled clinical studies to assess the use of BOTOX Cosmetic in the improvement of the appearance of glabellar lines.

Table 1: Adverse Reactions Reported by ≥1% of BOTOX Cosmetic treated Subjects and More Frequent than in Placebo-treated Subjects in Double-blind, Placebo-controlled Clinical Studies of Treatment of Glabellar Lines

Adverse Reactions by System Organ Class

General Disorders and Administration Site Conditions

Facial pain

Nervous System Disorders

Facial paresis

Eye Disorders

Eyelid ptosis

Musculoskeletal and Connective Tissue Disorders

Muscular Weakness

Lateral Canthal Lines

Table 2 lists selected adverse reactions reported within 90 days following injection by ≥1% of BOTOX Cosmetic treated subjects (N=526) aged 18 to 75 who were evaluated in two randomized, double-blind, placebo-controlled clinical studies to assess the use of BOTOX Cosmetic in the improvement of the appearance of lateral canthal lines alone.

Table 2: Adverse Reaction Reported by ≥1% of BOTOX Cosmetic Treated Subjects and More Frequent than in Placebo-treated Subjects Within 90 Days, in Double-blind, Placebo-controlled Clinical Studies of Treatment of Lateral Canthal Lines Adverse Reactions by System Organ

Eye disorders

edema

Forehead Lines

Table 3 lists selected adverse reactions reported by ≥1% of BOTOX Cosmetic treated subjects (N=665) aged 18 to 77 who were evaluated in two randomized, double-blind, placebo-controlled clinical studies to assess the use of BOTOX Cosmetic in the improvement of the appearance of forehead lines with glabellar lines.

Table 3: Adverse Reactions Reported by ≥1% of BOTOX Cosmetic treated Subjects More Frequently than in Placebo-treated Subjects, in Double-blind, Placebo-controlled Clinical Studies of Treatment of Forehead Lines

Adverse Reactions by System Organ Class BOTOX Cosmetic (20 Units forehead

and Subcutaneous

There were no additional adverse drug reactions reported with the simultaneous treatment of forehead lines, glabellar lines, and lateral canthal lines.

Platysma Bands

The safety of BOTOX Cosmetic (26 Units, 31 Units, or 36 Units) was evaluated in two double-blind, placebo-controlled, clinical trials with 407 BOTOX Cosmetic-treated subjects and 425 subjects receiving placebo. The safety profile of BOTOX Cosmetic treatment of platysma bands is consistent with the known safety profile of BOTOX Cosmetic for other indications.

Postmarketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin [see Warnings and Precautions]

There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease.

New onset or recurrent seizures have also been reported, typically in patients who are predisposed to experiencing these events.

The following adverse reactions by System Organ Class have been identified during post-approval use of BOTOX/BOTOX Cosmetic: Ear and labyrinth disorders Hypoacusis; tinnitus; vertigo

Eye disorders

Diplopia; dry eye; eyelid edema; lagophthalmos; strabismus; visual disturbances; vision blurred

Gastrointestinal disorders

Abdominal pain; diarrhea; dry mouth; nausea; vomiting

General disorders and administration site conditions

Denervation; malaise; pyrexia

Metabolism and nutrition disorders

Anorexia

Musculoskeletal and connective tissue disorders

Localized muscle twitching/involuntary muscle contractions; Mephisto sign; muscle atrophy; myalgia

Nervous system disorders

Brachial plexopathy; dysarthria; facial palsy; hypoaesthesia; localized numbness; myasthenia gravis; paresthesia; peripheral neuropathy; radiculopathy; syncope

Respiratory, thoracic and mediastinal disorders

Aspiration pneumonia; dyspnea; respiratory depression and/or respiratory failure

Skin and subcutaneous tissue disorders

Alopecia, including madarosis; hyperhidrosis; pruritus; skin rash (including erythema multiforme, dermatitis psoriasiform, and psoriasiform eruption)

DRUG INTERACTIONS

No formal drug interaction studies have been conducted with BOTOX Cosmetic (onabotulinumtoxinA) for injection.

Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission

Co-administration of BOTOX Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Anticholinergic Drugs

Use of anticholinergic drugs after administration of BOTOX Cosmetic may potentiate systemic anticholinergic effects.

Other Botulinum Neurotoxin Products

Muscle Relaxants

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX Cosmetic.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX Cosmetic in pregnant women.

In animal studies, administrations of BOTOX Cosmetic during pregnancy resulted in adverse effects on fetal growth (decreased fetal body weight and skeletal ossification) at clinically relevant doses, which were associated with maternal toxicity [see Data]

The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

When BOTOX Cosmetic (4, 8, or 16 Units/kg) was administered intramuscularly to pregnant mice or rats two times during the period of organogenesis (on gestation days 5 and 13), reductions in fetal body weight and decreased fetal skeletal ossification were observed at the two highest doses. The no-effect dose for developmental toxicity in these studies (4 Units/kg) is approximately 4 times the average high human dose for glabellar lines, lateral canthal lines, and forehead lines of 64 Units on a body weight basis (Units/kg).

When BOTOX Cosmetic was administered intramuscularly to pregnant rats (0.125, 0.25, 0.5, 1, 4, or 8 Units/kg) or rabbits (0.063, 0.125, 0.25, or 0.5 Units/kg) daily during the period of organogenesis (total of 12 doses in rats, 13 doses in rabbits), reduced fetal body weights and decreased fetal skeletal ossification were observed at the two highest doses in rats and at the highest dose in rabbits. These doses were also associated with

significant maternal toxicity, including abortions, early deliveries, and maternal death. The developmental no-effect doses in these studies of 1 Unit/kg in rats is approximately equal the average high human dose of 64 Units based on Units/kg, and the developmental no-effect dose of 0.25 Units/kg in rabbits is less than the average high human dose based on Units/kg.

When pregnant rats received single intramuscular injections (1, 4, or 16 Units/kg) at three different periods of development (prior to implantation, implantation, or organogenesis), no adverse effects on fetal development were observed. The developmental no-effect level for a single maternal dose in rats (16 Units/kg) is approximately 16 times the average high human dose of 64 Units based on Units/kg.

Lactation

Risk Summary

There are no data on the presence of BOTOX Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BOTOX Cosmetic and any potential adverse effects on the breastfed infant from BOTOX Cosmetic or from the underlying maternal conditions.

Pediatric Use

The safety and effectiveness of BOTOX Cosmetic have not been established in pediatric patients.

Geriatric Use

Glabellar Lines

In the two initial glabellar lines clinical studies of BOTOX Cosmetic, the responder rates appeared to be higher for subjects younger than age 65 than for subjects 65 years or older.

Lateral Canthal Lines

In the two lateral canthal lines clinical studies of BOTOX Cosmetic, the responder rates appeared to be higher for subjects younger than age 65 than for subjects 65 years or older.

Forehead Lines

In the two forehead lines clinical studies of BOTOX Cosmetic, the responder rates appeared to be higher for subjects younger than age 65 than for subjects 65 years or older.

Platysma Bands

In the two platysma bands clinical studies of BOTOX Cosmetic, 3.6% of subjects (13 subjects) treated with BOTOX Cosmetic were 65 years or older. Although the responder rates appeared to be higher for subjects younger than age 65 than for subjects 65 years or older, clinical studies of BOTOX Cosmetic did not include sufficient numbers of subjects 65 years or older to determine whether they respond differently from younger subjects.

OVERDOSAGE

Excessive doses of BOTOX Cosmetic (onabotulinumtoxinA) for injection may be expected to produce neuromuscular weakness with a variety of symptoms.

Symptoms of overdose are likely not to be present immediately following injection. Should accidental injection or oral ingestion occur or overdose be suspected, consider patients for further medical evaluation and immediately institute appropriate medical therapy, which may include hospitalization. The patient should be medically supervised for several weeks for signs and symptoms of systemic muscular weakness which could be local, or distant from the site of injection [see Boxed Warning and Warnings and Precautions]

If the musculature of the oropharynx and esophagus are affected, aspiration may occur which may lead to development of aspiration pneumonia. If the respiratory muscles become paralyzed or sufficiently weakened, intubation and assisted respiration may be necessary until recovery takes place.

Supportive care could involve the need for a tracheostomy and/or prolonged mechanical ventilation, in addition to other general supportive care.

In the event of overdose, antitoxin raised against botulinum toxin is available from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. However, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration. In the event of suspected or actual cases of botulinum toxin poisoning, please contact your local or state Health Department to process a request for antitoxin through the CDC. If you do not receive a response within 30 minutes, please contact the CDC directly at 1-770-488-7100. More information can be obtained at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5232a8.htm.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed to evaluate carcinogenic potential of BOTOX Cosmetic.

BOTOX Cosmetic was negative in a battery of in vitro (microbial reverse mutation assay, mammalian cell mutation assay, and chromosomal aberration assay) and in vivo (micronucleus assay) genetic toxicologic assays.

In fertility studies of BOTOX Cosmetic (4, 8, or 16 Units/kg) in which either male or female rats were injected intramuscularly prior to mating and on the day of mating (3 doses, 2 weeks apart for males, 2 doses, 2 weeks apart for females) to untreated animals, reduced fertility was observed in males at the intermediate and high doses and in females at the high dose. The no-effect doses for reproductive toxicity (4 Units/kg in males, 8 Units/kg in females) are approximately 4-8 times the average high human dose for glabellar lines, lateral canthal lines, and forehead lines of 64 Units on a body weight basis (Units/kg).

PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Provide a copy of the Medication Guide and review the contents with the patient.

Swallowing, Speaking or Breathing Difficulties, or Other Unusual Symptoms

Advise patients to inform their doctor or pharmacist if they develop any unusual symptoms (including difficulty with swallowing, speaking, or breathing), or if any existing symptom worsens [see Boxed Warning and Warnings and Precautions]

Ability to Operate Machinery or Vehicles

Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, avoid driving a car or engaging in other potentially hazardous activities.

Ophthalmic Adverse Reactions

Inform patients that BOTOX Cosmetic injection may cause eye dryness. Advise patients to report symptoms of eye dryness (e.g., eye pain, eye irritation, photosensitivity, or changes in vision) to their doctor.

Manufactured by: AbbVie Inc.

1 N Waukegan Rd. North Chicago, IL 60064

U.S. License number 1889

Ref: V4.1USPI3919 Revised: October 2024

A Natural Choice

For Your Practice & Your Patients

Renuva is an off-the-shelf allograft adipose matrix. When injected, the matrix functions as a scaffold that the body replaces with the patient’s own fat Over the course of 3-6 months post treatment Renuva is eliminated by the body, leaving only the patient’s own new fat exactly where desired.

Renuva undergoes a rigorous processing method that removes all DNA, cells or live components retaining the naturally-occurring proteins, collagen and growth factors found in native fat.

While Renuva is injected similarly to HA fillers and biostimulants, it does not fill space Instead, it helps restore volume where fat loss has occurred, or where fat is desired The resulting fat is not hydrophilic and does not migrate

Portrait provides expert consulting, technology, and resources to help med spas thrive. From medical oversight and compliance to patient acquisition and finance, we empower you to achieve sustainable growth and profitability.

Attract and retain patients with proven coaching, playbooks, memberships, SMS campaigns, and website optimization.

Streamline operations with our integrated EMR, medical oversight, financing solutions, supplier network, and growth strategies.

Ensure compliance, optimize treatment planning, and access top-tier MDs with our matching service, training programs, and malpractice support.

Leverage our EHR, scheduling, CRM, marketing automation, patient portal, and inventory management tools for seamless workflows.

Maximize efficiency with support for supplier relations, real estate, expansion, payroll, HR, and medical assistant staffing.

More than 800 providers nationwide have partnered with Portrait for the management and expansion of their med spas.

Get Your Free Consultation | @portraitproviders

Actual Renuva Patient

Optimize patients’ results with the only neuromodulator formulated with Peptide Exchange Technology ™4-8

*Results as early as the next day and typically within 2 days. At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Improves the appearance of skin texture versus before treatment. 64% of patients achieved an improvement in the appearance of skin texture at week 2 from a post hoc analysis of a Phase 2 clinical study with 60 patients. 74% achieved a > 2-grade improvement at week 4 per both investigator’s and patient’s assessments.1,2-4,9

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s). Warnings and Precautions Please refer to Boxed Warning for Distant Spread of Toxin Effect. The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products.

Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment. Adverse Reactions The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%). Drug Interactions Co-administration of DAXXIFY and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown. Use in Specific Populations DAXXIFY® is not recommended for use in children or pregnant women. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide, at RevanceAesthetics.com.

REFERENCES

1. Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc; 2021. 2. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845. 3. Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc; 2023. 4. DAXXIFY® Prescribing Information. Revance Therapeutics, Inc; 2023. 5. Botox® Cosmetic. Prescribing Information. Allergan Inc; 2023. 6. Xeomin . Prescribing Information. Merz Pharmaceuticals GmbH; 2024. 7. Dysport® Prescribing Information. Ipsen Biopharmaceuticals Ltd; 2023. 8. Jeuveau® Prescribing Information. Evolus, Inc; 2020. 9. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebocontrolled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.

©2025 REVANCE AESTHETICS. DAXXIFY, Revance Therapeutics, and the Revance logo are registered trademarks of Revance Therapeutics Inc. All other trademarks are the property of their respective owners. DX00487 DAXI-01259

DX00487 LAMCA 2025 Print Ad v05.indd 1 2/20/25 5:52 PM